A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Inclusion Criteria:

• Provide written informed consent

• Age ≥18 years or legal age of majority if >18 years in the participant's country ofresidence

• Current hospitalization or recently discharged (during or within 30 days ofdischarge) with the primary diagnosis of heart failure

• Heart failure signs and symptoms at the time of hospital admission

• Imaging evidence of mildly reduced or preserved left ventricular ejection fraction (EF) (40% or higher)

• Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg/mL or B-typenatriuretic peptide (BNP) ≥125 pg/mL for patients without atrial fibrillation (AF);or elevated NTproBNP ≥1500 pg/mL or BNP ≥375 pg/mL for patients with AF

Exclusion Criteria:

• Current or planned long-term treatment with a mineralocorticoid receptor antagonist (MRA)

• Documented prior history of severe hyperkalemia in the setting of MRA use

• Estimated glomerular filtration rate (eGFR) <25 mL/min/1.73m² or potassium >5.0mmol/L at screening

• Acute myocardial infarction due to plaque rupture, coronary revascularization, valvereplacement/repair, or implantation of a cardiac resynchronization therapy devicewithin 30 days

• Hemodynamically significant (severe) uncorrected primary cardiac valvular disease

• Cardiomyopathy due to known acute inflammatory heart, infiltrative diseases,accumulation diseases, muscular dystrophies, cardiomyopathy with reversible causes,known hypertrophic obstructive cardiomyopathy, complex congenital heart disease, orknown pericardial constriction

• Probable alternative cause of participant's heart failure symptoms

• Concomitant systemic therapy with potent cytochrome P450 isoenzyme 3A4 (CYP3A4)inhibitors or moderate CYP3A4 inducers, or potent CYP3A4 inducers

• Known hypersensitivity to the IP (active substance or excipients)